Last reviewed · How we verify
NCT06160596: ROSALIND
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
trial testing Long term survival multimodal analysis in Pancreas Adenocarcinoma in 1,020 participants. Currently enrolling.
1 November 2025
Quick facts
| Lead sponsor | Cure 51 |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,020 |
| Start date | 1 November 2023 |
| Primary completion | 1 November 2025 |
| Estimated completion | 1 May 2028 |
| Sites | 1 location across France |
Drugs / interventions tested
- Long term survival multimodal analysis
Conditions studied
- Pancreas Adenocarcinoma — all drugs for Pancreas Adenocarcinoma →
- Small-cell Lung Cancer — all drugs for Small-cell Lung Cancer →
- Glioblastoma, IDH-wildtype — all drugs for Glioblastoma, IDH-wildtype →
Sponsor
Cure 51
Who can join
18 and older, any sex, with Pancreas Adenocarcinoma or Small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a retrospective, exploratory, multi-center, translational, 3 cohorts case control matched study conducted in patients harboring a solid tumor with poor prognosis who presented a long-term (case) and standard (standard) survival. Patients with: * Cohort A: metastatic pancreatic ductal adenocarcinoma * Cohort B: glioblastoma IDHwt * Cohort C: extensive small cell lung cancer This research aims to integrate data generated from clinical records, imaging, multi-omics and bioinformatics approaches to discriminate case and control and then to identify new therapeutic targets. Analyses will be performed depending on the tumor samples available with at least 3 omics levels and according to scientific advances; genomic, epigenomic, proteomics, metabolomics, transcriptomic, microbiomic.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06160596
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreas Adenocarcinoma
Currently open trials in the same condition.
- NCT07043270 — 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC · Phase 2 · recruiting
- NCT07262957 — Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Inc · Phase 4 · recruiting
- NCT07081360 — Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer · Phase 3 · recruiting
- NCT07022015 — Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy · NA · recruiting
- NCT06497777 — The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06160596 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cure 51
- Last refreshed: 7 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06160596.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing